shiftingbio builds biotech companies on a virtual operating model. Programs are designed and directed centrally, while preclinical and early clinical development is executed with leading partners in China.
This approach significantly reduces development timelines and capital requirements without compromising quality.
It reflects a structural shift in the industry: traditional biotech R&D models are increasingly under pressure, while China has emerged as one of the most advanced and capital-efficient drug development ecosystems globally.